This HTML5 document contains 47 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n14http://localhost/temp/predkladatel/
n8http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n6http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n4http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216224%3A14110%2F07%3A00032969%21RIV10-MSM-14110___/
n11http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n16http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n15http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n12http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n17http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n10http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n7http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216224%3A14110%2F07%3A00032969%21RIV10-MSM-14110___
rdf:type
n6:Vysledek skos:Concept
dcterms:description
OBJECTIVE: The objective of the study was to evaluate the effect of administration of the immunoregulating preparation Immodin (Sevapharma, CZ) to influence immunoparalysis in intensive care unit patients. METHOD: A double blind, randomised clinical study was designed for the above purpose. The patients in whom immunoparalysis was detected during monitoring (CD14+ HLA-DR+ < or = 40 %) were randomised for the administration of Immodin (IM) or placebo (PL); the treatment lasted for 5 days. 45 (25% of all monitored) patients - the men/women ratio being 29/16, 60 (54; 65) years of age - were enrolled in the study (of which 25 IM and 20 PL). RESULTS: The patients did not show differences in ICU mortality - 23 IM patients survived, 2 IM patients died; 15 PL patients survived and 5 PL patients died (p = 0.214). The time of ICU hospitalisation did not differ, either - 11.6 days for IM patients (8.2; 14.9), 12.6 days for PL patients (9.1; 16.1) (P = 0. OBJECTIVE: The objective of the study was to evaluate the effect of administration of the immunoregulating preparation Immodin (Sevapharma, CZ) to influence immunoparalysis in intensive care unit patients. METHOD: A double blind, randomised clinical study was designed for the above purpose. The patients in whom immunoparalysis was detected during monitoring (CD14+ HLA-DR+ < or = 40 %) were randomised for the administration of Immodin (IM) or placebo (PL); the treatment lasted for 5 days. 45 (25% of all monitored) patients - the men/women ratio being 29/16, 60 (54; 65) years of age - were enrolled in the study (of which 25 IM and 20 PL). RESULTS: The patients did not show differences in ICU mortality - 23 IM patients survived, 2 IM patients died; 15 PL patients survived and 5 PL patients died (p = 0.214). The time of ICU hospitalisation did not differ, either - 11.6 days for IM patients (8.2; 14.9), 12.6 days for PL patients (9.1; 16.1) (P = 0. OBJECTIVE: The objective of the study was to evaluate the effect of administration of the immunoregulating preparation Immodin (Sevapharma, CZ) to influence immunoparalysis in intensive care unit patients. METHOD: A double blind, randomised clinical study was designed for the above purpose. The patients in whom immunoparalysis was detected during monitoring (CD14+ HLA-DR+ < or = 40 %) were randomised for the administration of Immodin (IM) or placebo (PL); the treatment lasted for 5 days. 45 (25% of all monitored) patients - the men/women ratio being 29/16, 60 (54; 65) years of age - were enrolled in the study (of which 25 IM and 20 PL). RESULTS: The patients did not show differences in ICU mortality - 23 IM patients survived, 2 IM patients died; 15 PL patients survived and 5 PL patients died (p = 0.214). The time of ICU hospitalisation did not differ, either - 11.6 days for IM patients (8.2; 14.9), 12.6 days for PL patients (9.1; 16.1) (P = 0.
dcterms:title
Immodin in the treatment of immunoparalysis in intensive care patients Immodin in the treatment of immunoparalysis in intensive care patients Immodin in the treatment of immunoparalysis in intensive care patients
skos:prefLabel
Immodin in the treatment of immunoparalysis in intensive care patients Immodin in the treatment of immunoparalysis in intensive care patients Immodin in the treatment of immunoparalysis in intensive care patients
skos:notation
RIV/00216224:14110/07:00032969!RIV10-MSM-14110___
n3:aktivita
n15:V
n3:aktivity
V
n3:cisloPeriodika
9
n3:dodaniDat
n7:2010
n3:domaciTvurceVysledku
n8:7303971 n8:1852698 n8:8940762 n8:8396043
n3:druhVysledku
n17:J
n3:duvernostUdaju
n16:S
n3:entitaPredkladatele
n4:predkladatel
n3:idSjednocenehoVysledku
425516
n3:idVysledku
RIV/00216224:14110/07:00032969
n3:jazykVysledku
n12:cze
n3:klicovaSlova
intensive care unit patients; immunoparalysis; Immodin
n3:klicoveSlovo
n11:immunoparalysis n11:Immodin n11:intensive%20care%20unit%20patients
n3:kodStatuVydavatele
CZ - Česká republika
n3:kontrolniKodProRIV
[ABA00187CBC3]
n3:nazevZdroje
Vnitřní lékařství
n3:obor
n10:FE
n3:pocetDomacichTvurcuVysledku
4
n3:pocetTvurcuVysledku
6
n3:rokUplatneniVysledku
n7:2007
n3:svazekPeriodika
53
n3:tvurceVysledku
Šrámek, Vladimír Kuklínek, Pavel Šťouračová, M. Burešová, Lucie Šťetka, P. Dadák, Lukáš
s:issn
0042-773X
s:numberOfPages
6
n14:organizacniJednotka
14110